Goldman Sachs Group Inc. Has $135.79 Million Stock Position in Natera, Inc. $NTRA

Key Points

• Goldman Sachs Group Inc. reduced its holdings in Natera, Inc. by 43.3%, now owning approximately 0.70% of the company valued at about $135.8 million.
• Natera reported a quarterly revenue of $546.6 million, surpassing estimates, but had an earnings per share of ($0.74), missing the consensus estimate of ($0.60).
• Analysts have mixed ratings on Natera, with Barclays maintaining an "overweight" rating and setting a target price of $210.00, while Wall Street Zen downgraded the stock to "sell."

Goldman Sachs Group Inc. decreased its position in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) by 43.3% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 960,280 shares of the medical research company's stock after selling 734,551 shares during the quarter. Goldman Sachs Group Inc. owned 0.70% of Natera worth $135,793,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in NTRA. Bank of Jackson Hole Trust purchased a new position in Natera in the 1st quarter valued at $29,000. Rakuten Securities Inc. grew its position in shares of Natera by 117.8% during the first quarter. Rakuten Securities Inc. now owns 220 shares of the medical research company's stock worth $31,000 after buying an additional 119 shares in the last quarter. ORG Partners LLC acquired a new position in shares of Natera during the first quarter worth about $32,000. TCTC Holdings LLC grew its position in shares of Natera by 114.8% during the first quarter. TCTC Holdings LLC now owns 232 shares of the medical research company's stock worth $33,000 after buying an additional 124 shares in the last quarter. Finally, Northwestern Mutual Wealth Management Co. boosted its holdings in Natera by 83.5% in the first quarter. Northwestern Mutual Wealth Management Co. now owns 233 shares of the medical research company's stock valued at $33,000 after purchasing an additional 106 shares in the last quarter. Hedge funds and other institutional investors own 99.90% of the company's stock.

Natera Stock Down 3.0%

Natera stock traded down $5.30 during mid-day trading on Friday, hitting $168.51. 853,091 shares of the company's stock traded hands, compared to its average volume of 978,479. Natera, Inc. has a one year low of $117.27 and a one year high of $183.00. The firm has a 50 day moving average price of $155.18 and a 200 day moving average price of $154.12. The company has a market cap of $23.13 billion, a PE ratio of -88.23 and a beta of 1.68.

Natera (NASDAQ:NTRA - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The medical research company reported ($0.74) EPS for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.14). Natera had a negative return on equity of 22.22% and a negative net margin of 12.89%.The firm had revenue of $546.60 million during the quarter, compared to the consensus estimate of $476.84 million. During the same period in the prior year, the firm posted ($0.30) EPS. The firm's quarterly revenue was up 32.2% on a year-over-year basis. Natera has set its FY 2025 guidance at EPS. On average, analysts expect that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Insider Activity at Natera

In other news, insider John Fesko sold 678 shares of the business's stock in a transaction on Thursday, August 14th. The stock was sold at an average price of $155.46, for a total transaction of $105,401.88. Following the sale, the insider directly owned 152,747 shares of the company's stock, valued at $23,746,048.62. The trade was a 0.44% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Rowan E. Chapman sold 2,750 shares of the business's stock in a transaction dated Thursday, August 28th. The shares were sold at an average price of $166.99, for a total value of $459,222.50. Following the completion of the transaction, the director owned 6,015 shares in the company, valued at $1,004,444.85. This trade represents a 31.37% decrease in their position. The disclosure for this sale can be found here. Insiders sold 56,423 shares of company stock valued at $8,459,656 over the last ninety days. Company insiders own 5.63% of the company's stock.

Analysts Set New Price Targets

A number of brokerages have weighed in on NTRA. Morgan Stanley reiterated an "overweight" rating and issued a $195.00 price objective on shares of Natera in a research note on Sunday, August 10th. Barclays reaffirmed an "overweight" rating and set a $210.00 price objective (up previously from $190.00) on shares of Natera in a research note on Friday, August 8th. Stephens reaffirmed an "overweight" rating and set a $183.00 price objective on shares of Natera in a research note on Friday, August 15th. Piper Sandler reissued an "overweight" rating and issued a $220.00 price target (up from $210.00) on shares of Natera in a research note on Monday, August 11th. Finally, Evercore ISI upgraded Natera to a "strong-buy" rating and set a $170.00 price objective on the stock in a report on Monday, July 28th. One analyst has rated the stock with a Strong Buy rating and seventeen have given a Buy rating to the company. According to data from MarketBeat, the company presently has an average rating of "Buy" and a consensus target price of $194.00.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.